Controlled human malaria infections by intradermal injection of cryopreserved Plasmodium falciparum sporozoites - PubMed (original) (raw)

Clinical Trial

doi: 10.4269/ajtmh.2012.12-0613. Epub 2012 Nov 13.

Else M Bijker, B Kim Lee Sim, Peter F Billingsley, Eric R James, Guido J H Bastiaens, Anne C Teirlinck, Anja Scholzen, Karina Teelen, Theo Arens, André J A M van der Ven, Anusha Gunasekera, Sumana Chakravarty, Soundarapandian Velmurugan, Cornelus C Hermsen, Robert W Sauerwein, Stephen L Hoffman

Clinical Trial

Controlled human malaria infections by intradermal injection of cryopreserved Plasmodium falciparum sporozoites

Meta Roestenberg et al. Am J Trop Med Hyg. 2013 Jan.

Abstract

Controlled human malaria infection with sporozoites is a standardized and powerful tool for evaluation of malaria vaccine and drug efficacy but so far only applied by exposure to bites of Plasmodium falciparum (Pf)-infected mosquitoes. We assessed in an open label Phase 1 trial, infection after intradermal injection of respectively 2,500, 10,000, or 25,000 aseptic, purified, vialed, cryopreserved Pf sporozoites (PfSPZ) in three groups (N = 6/group) of healthy Dutch volunteers. Infection was safe and parasitemia developed in 15 of 18 volunteers (84%), 5 of 6 volunteers in each group. There were no differences between groups in time until parasitemia by microscopy or quantitative polymerase chain reaction, parasite kinetics, clinical symptoms, or laboratory values. This is the first successful infection by needle and syringe with PfSPZ manufactured in compliance with regulatory standards. After further optimization, the use of such PfSPZ may facilitate and accelerate clinical development of novel malaria drugs and vaccines.

PubMed Disclaimer

Conflict of interest statement

Disclosure: Sanaria Inc. manufactured PfSPZ Challenge, and Protein Potential LLC is affiliated with Sanaria. Thus, all authors associated with Sanaria or Protein Potential have potential conflicts of interest. There are no other conflicts of interest.

Figures

Figure 1.

Figure 1.

Parasite density as measured by quantitative polymerase chain reaction (qPCR) in the 2,500 (A), 10,000 (B), and 25,000 (C) PfSPZ Challenge dose groups. Panels A, B, and C show geometric mean parasite density of positive volunteers per group with confidence intervals (N = 5 for all groups) from day of inoculation through last day of positivity after initiation of treatment. Panel D shows an overlay of geometric mean parasite densities of positive volunteers in each group.

Figure 2.

Figure 2.

Number of possibly, probably, or definitely related solicited and unsolicited adverse events reported over time in the 2,500 (black dashed), 10,000 (red dotted), and 25,000 PfSPZ Challenge dose (green straight) groups.

Comment in

References

    1. World Health Organization, Global Malaria Programme . World Malaria Report 2010: World Health Organization. 2010.
    1. Murray CJ, Rosenfeld LC, Lim SS, Andrews KG, Foreman KJ, Haring D, Fullman N, Naghavi M, Lozano R, Lopez AD. Global malaria mortality between 1980 and 2010: a systematic analysis. Lancet. 2012;379:413–431. -PubMed
    1. Alonso PL, Brown G, Arevalo-Herrera M, Binka F, Chitnis C, Collins F, Doumbo OK, Greenwood B, Hall BF, Levine MM, Mendis K, Newman RD, Plowe CV, Rodriguez MH, Sinden R, Slutsker L, Tanner M. A research agenda to underpin malaria eradication. PLoS Med. 2011;8:e1000406. -PMC -PubMed
    1. Najera JA, Gonzalez-Silva M, Alonso PL. Some lessons for the future from the Global Malaria Eradication Programme (1955–1969) PLoS Med. 2011;8:e1000412. -PMC -PubMed
    1. Sauerwein RW, Roestenberg M, Moorthy VS. Experimental human challenge infections can accelerate clinical malaria vaccine development. Nat Rev Immunol. 2011;11:57–64. -PubMed

Publication types

MeSH terms

Grants and funding

LinkOut - more resources